One patent currently held, every record listed here
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jul 2027. from the record
Of the 3 now held by other companies, 3 name Musc Foundation for Research Development as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
1
Ending by 2030
Jul 2027
Next term end
1
Patent families
When these terms end
Each bar runs from grant to computed term end. 2011 to 2028.
US 8,735,365
Targeting PAX2 for the Induction of DEFB1-MEDIATED Tumor Immunity and Cancer Therapy
no later than Jul 7, 2027
US 7,964,577
Targeting PAX2 for the Induction of DEFB1-MEDIATED Tumor Immunity and Cancer Therapy
Jul 27, 2027
20152019202320272028
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
Every computed term in this portfolio is shown above.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends no later than Jan 2028 · Low confidence
The largest patent family in this portfolio, 29 related applications, renewed at 3 of 3 maintenance windows. Protection runs to 2028. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
now held by Musc Foundation for Research Development
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- 6 terms have ended since Aug 16, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Targeting PAX2 for the Induction of DEFB1-MEDIATED Tumor Immunity and Cancer Therapy | 1 in force | to Jul 2027 |
Patents held now
Soonest term end first.
Showing 1 to 1 of 1
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,964,577 | Targeting PAX2 for the Induction of DEFB1-MEDIATED Tumor Immunity and Cancer Therapy In force · High confidence | In force | High confidence |
Also on record, not counted in the 1: 3 patents in force now held by others · 11 patents ended · 12 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
4 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed
4 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.